American Century Companies Inc. Purchases 264,254 Shares of SiBone $SIBN

Key Points

• American Century Companies Inc. increased its stake in SiBone by 11.1%, now owning approximately 2,642,322 shares valued at $37 million.
• Other institutional investors have also significantly increased their stakes, with Russell Investments Group Ltd. growing its position by 765.3% during the same quarter.
• SiBone reported better-than-expected earnings, with a revenue of $48.63 million, surpassing analysts' estimates, and currently holds a consensus rating of "Buy" among analysts.

American Century Companies Inc. increased its holdings in SiBone (NASDAQ:SIBN - Free Report) by 11.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,642,322 shares of the company's stock after purchasing an additional 264,254 shares during the quarter. American Century Companies Inc. owned approximately 6.20% of SiBone worth $37,072,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in SiBone by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock valued at $328,000 after acquiring an additional 988 shares during the last quarter. Invesco Ltd. boosted its position in SiBone by 8.9% during the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after acquiring an additional 1,413 shares during the last quarter. Rhumbline Advisers boosted its position in SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after acquiring an additional 2,100 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in SiBone during the first quarter valued at $34,000. Finally, Barclays PLC boosted its position in SiBone by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after acquiring an additional 2,589 shares during the last quarter. Institutional investors own 98.11% of the company's stock.

SiBone Stock Up 2.3%

SIBN stock traded up $0.37 during mid-day trading on Tuesday, reaching $16.42. 285,494 shares of the company traded hands, compared to its average volume of 517,766. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. The firm's 50 day moving average price is $17.01 and its 200 day moving average price is $16.51. The stock has a market cap of $708.36 million, a price-to-earnings ratio of -29.32 and a beta of 0.91. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The firm had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. SiBone has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that SiBone will post -0.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SIBN has been the topic of a number of research analyst reports. Wall Street Zen cut shares of SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the company an "overweight" rating in a report on Monday, August 11th. Truist Financial upped their price objective on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of SiBone in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $23.67.

Insider Activity

In other SiBone news, SVP Michael A. Pisetsky sold 3,329 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.64, for a total transaction of $52,065.56. Following the completion of the sale, the senior vice president directly owned 258,352 shares of the company's stock, valued at approximately $4,040,625.28. The trade was a 1.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Anshul Maheshwari sold 3,461 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.57, for a total value of $53,887.77. Following the sale, the chief financial officer directly owned 214,445 shares of the company's stock, valued at $3,338,908.65. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 49,967 shares of company stock worth $829,469. Company insiders own 3.90% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.